Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A minimalist representation of a drug compound in a flat design style.

Jun 7, 2026

Reid Hoffman’s Shift Spurs AI Biotech Innovation Wave

Reid Hoffman's recent transition from Microsoft to a more active role in AI-driven biotech signifies a notable shift in the industry landscape, particularly in the oncology sector.Hoffman's departure from Microsoft's board, announced in a recent filing, marks a strategic move back to his entrepreneurial roots. This change comes as he joins Manas AI, a biotech startup focused on leveraging artificial intelligence for drug discovery. With significant funding already secured, including a $50.6 mill
A vial of biologic solution on a laboratory countertop in a dimly lit setting.

Jun 6, 2026

Assessing ADMA Biologics (ADMA) Valuation After Legal Probes Short Seller Claims And Guidance Withdrawal

ADMA Biologics is currently facing significant challenges, including legal investigations and a critical report from short sellers, leading to a withdrawal of long-term guidance and a notable drop in stock price.The company has seen its shares decline by 20.9% in the past month and 55.4% year-to-date, despite a strong five-year total shareholder return. With ADMA's stock priced at $7.97, analysts have set an average target of $16.75, raising questions about whether the market is undervaluing fut
A minimalist representation of a medical device and software integration in flat design.

Jun 6, 2026

Moving from Hardware-Centric Systems to Software-as-a-Medical-Device (SaMD)

The healthcare landscape is experiencing a significant shift from hardware-centric systems to Software-as-a-Medical-Device (SaMD), driven by the increasing role of intelligent software in diagnostics.This transformation is particularly crucial in regions with a shortage of specialized medical professionals, such as India, where AI-powered SaMD solutions can automate real-time data analysis. This alleviates the pressure on scarce radiologists and cardiologists, enabling quicker clinical decision-
A scientific notebook and pen in a laboratory setting

Jun 6, 2026

Agilent Partners With OpenAI and BCG to Scale AI Across Products, Operations, and Customer Workflows

Agilent Technologies has entered into a strategic partnership with OpenAI and Boston Consulting Group (BCG) to enhance the integration of artificial intelligence (AI) within its operations and product offerings.This collaboration aims to leverage Agilent's scientific expertise and data resources alongside OpenAI's AI research capabilities and BCG's experience in enterprise transformation. The goal is to identify and scale AI applications that can improve Agilent's business processes and customer
Surgical gloves on a hospital supply table

Jun 6, 2026

IHH Healthcare Taps Infosys in a Seven-Year Deal to Build AI-Powered ERP Platform Across Global Hospital Network

IHH Healthcare has partnered with Infosys in a significant seven-year agreement to develop an AI-enhanced ERP platform aimed at streamlining operations across its extensive global network of healthcare facilities.The new system, leveraging Oracle technology, is designed to unify procurement and supply chain activities, improving operational efficiency and data-driven decision-making. With nearly 190 healthcare facilities, including 89 hospitals in 10 countries, IHH Healthcare is one of the large
A minimalist representation of a drug compound molecule in a dark color scheme.

Jun 6, 2026

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Down 14.8% After ASCO NSCLC Data Spotlight - Has The Bull Case Changed?

Sichuan Kelun-Biotech Biopharmaceutical recently faced a 14.8% decline following its presentations at the 2026 ASCO Annual Meeting, where it showcased promising data on its oncology pipeline, particularly for non-small cell lung cancer (NSCLC).The company highlighted findings from its Phase III and Phase II trials, notably the combination of sacituzumab tirumotecan and pembrolizumab, which demonstrated improved progression-free survival compared to pembrolizumab alone. Additionally, lunbotinib f
A minimalist illustration of a vaccine vial and virus silhouette in dark colors.

Jun 6, 2026

‘World-First’ AI-Designed Vaccine Enters Human Trial, Aiming to Protect Against Future Pandemic Threats

A groundbreaking AI-designed vaccine is entering human trials, aimed at enhancing preparedness for future pandemics by targeting multiple coronaviruses simultaneously.Researchers from the University of Cambridge have initiated the first successful human trial of a vaccine whose key antigen was entirely created using artificial intelligence. This innovative vaccine is designed to combat various coronaviruses, including current COVID-19 variants and animal strains that could potentially lead to fu
A hospital bed in a dimly lit room with a medical chart on the table.

Jun 6, 2026

Paras Healthcare Refiles INR 1,800 Cr IPO, Plans Expansion to 3,011 Beds by FY28

Paras Healthcare is making a renewed push to enter the public market with a proposed INR 1,800 crore IPO, aiming to expand its hospital bed capacity significantly by FY28.The company’s IPO plan includes a fresh issue of INR 500 crore and an offer for sale of up to INR 1,300 crore by existing shareholders. This marks Paras Healthcare's second attempt to list on Indian stock exchanges in under two years, following a previous attempt that fell through despite regulatory approval in 2024.Founded in
Flat illustration of siRNA molecule and AI model

Jun 6, 2026

How a US$2 Billion Generative AI RNAi Deal At Alnylam Pharmaceuticals (ALNY) Has Changed Its Investment Story

Alnylam Pharmaceuticals has entered a significant partnership with Inceptive Nucleics, valued at up to $2 billion, aimed at leveraging generative AI to enhance RNAi drug discovery. This collaboration includes an initial investment of $30 million and grants Alnylam access to advanced AI models and expertise, notably from Transformer co-inventor Jakob Uszkoreit, to improve siRNA design and overall research productivity.This partnership is poised to reshape Alnylam's investment narrative as it seek
A minimalist representation of a molecule and a computer chip, symbolizing AI in drug discovery.

Jun 6, 2026

NYB.AI Featured in NVIDIA GTC Taiwan

NYB.AI, an AI-driven drug discovery platform, has gained recognition at NVIDIA GTC Taiwan 2026, showcasing its innovative potential in the life sciences sector.Developed by Nanyang Biologics, NYB.AI was highlighted in the opening showcase video at the event, which featured select companies from the NVIDIA Inception ecosystem. This recognition underscores the growing global interest in integrating artificial intelligence with biology and high-performance computing to enhance drug discovery proces
A tissue sample on a laboratory countertop with a notebook in the background.

Jun 6, 2026

Is Tempus AI’s (TEM) New Oncology Tools Quietly Redefining Its Precision Medicine Moat?

Tempus AI is making significant strides in oncology with recent advancements that include FDA approval for its xT CDx tumor-only sequencing platform and the upcoming launch of its xH whole-genome test. These innovations are part of a broader strategy to integrate AI into precision medicine, aiming to create a comprehensive infrastructure for diagnostics and drug development.With the FDA's endorsement of the xT CDx platform, Tempus AI is poised to enhance its market position by potentially conver
A quantum encryption chip on a lab countertop in a dimly lit research lab.

Jun 6, 2026

Redwood AI Piles on the News Flow: Patent, Quantum Deal, and Government Cash

Redwood AI has recently generated significant investor interest, with its stock climbing nearly 10% following a series of strategic announcements. These developments encompass a quantum acquisition, a new patent, and government funding aimed at enhancing its capabilities in the life sciences sector.The most notable announcement involves Redwood AI's intention to acquire Quantum.IQ, a company specializing in quantum-resistant encryption. This acquisition, still subject to due diligence and regula